Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Biogen: What To Do Ahead Of Q4 2022 Financial Report
07:12am, Monday, 06'th Feb 2023 Seeking Alpha
Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
11:34am, Thursday, 02'nd Feb 2023 Benzinga
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. Meta Platform Inc’s (NASDAQ: META) strong earnings could set the tempo for the market mood as tr
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
06:25pm, Wednesday, 01'st Feb 2023 Zacks Investment Research
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
05:30pm, Wednesday, 01'st Feb 2023 The Motley Fool
NVS earnings call for the period ending December 31, 2022.
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
03:03pm, Wednesday, 01'st Feb 2023
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
11:56am, Wednesday, 01'st Feb 2023 Benzinga
Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon.
Cues From Tuesday’s Trading:
Stocks closed
Novartis AG (NVS) Q4 2022 Earnings Call Transcript
10:15am, Wednesday, 01'st Feb 2023
Novartis AG (NYSE:NVS ) Q4 2022 Earnings Conference Call February 1, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Har
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
09:16am, Wednesday, 01'st Feb 2023
GSK stock and NVO stock rose Wednesday on fourth-quarter beats, but Novartis stock fell on lighter-than-expected sales despite strong profit. The post Pharma Giants GSK, Novo Nordisk Beat Expectations
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividend
01:39am, Wednesday, 01'st Feb 2023
By Cecilia Butini
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
03:31pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?
12:32pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.
Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?
04:28pm, Friday, 27'th Jan 2023 Zacks Investment Research
Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
02:36pm, Friday, 27'th Jan 2023 Zacks Investment Research
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.
Could This Be Novartis' Next Blockbuster Medicine?
01:45pm, Friday, 27'th Jan 2023 The Motley Fool
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
01:14pm, Friday, 27'th Jan 2023 Zacks Investment Research
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
